ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $3,106,000 | -28.3% | 42,776 | -17.0% | 0.00% | 0.0% |
| Q4 2021 | $4,332,000 | -9.2% | 51,522 | -2.6% | 0.00% | -33.3% |
| Q3 2021 | $4,773,000 | +8.9% | 52,924 | +15.2% | 0.00% | +50.0% |
| Q2 2021 | $4,382,000 | -54.1% | 45,958 | -45.2% | 0.00% | -60.0% |
| Q1 2021 | $9,549,000 | -30.7% | 83,862 | -15.7% | 0.01% | -44.4% |
| Q4 2020 | $13,776,000 | +89.4% | 99,513 | +12.5% | 0.01% | +80.0% |
| Q3 2020 | $7,272,000 | +116.6% | 88,473 | +106.1% | 0.01% | +66.7% |
| Q2 2020 | $3,358,000 | +128.0% | 42,934 | +29.5% | 0.00% | +200.0% |
| Q1 2020 | $1,473,000 | +21.7% | 33,151 | +17.0% | 0.00% | 0.0% |
| Q4 2019 | $1,210,000 | +22.3% | 28,333 | +22.5% | 0.00% | 0.0% |
| Q3 2019 | $989,000 | -22.1% | 23,125 | +15.6% | 0.00% | 0.0% |
| Q2 2019 | $1,270,000 | -5.2% | 20,006 | +3.7% | 0.00% | 0.0% |
| Q1 2019 | $1,339,000 | +95.5% | 19,301 | +22.6% | 0.00% | 0.0% |
| Q4 2018 | $685,000 | -55.7% | 15,744 | -22.3% | 0.00% | 0.0% |
| Q3 2018 | $1,547,000 | +5.6% | 20,262 | +6.3% | 0.00% | 0.0% |
| Q2 2018 | $1,465,000 | +60.8% | 19,054 | +6.7% | 0.00% | 0.0% |
| Q1 2018 | $911,000 | -11.0% | 17,858 | -19.1% | 0.00% | 0.0% |
| Q4 2017 | $1,024,000 | +43.0% | 22,075 | +64.1% | 0.00% | 0.0% |
| Q3 2017 | $716,000 | -17.0% | 13,449 | -3.2% | 0.00% | 0.0% |
| Q2 2017 | $863,000 | -61.1% | 13,888 | -57.6% | 0.00% | -66.7% |
| Q1 2017 | $2,220,000 | +29.4% | 32,751 | +34.2% | 0.00% | +50.0% |
| Q4 2016 | $1,715,000 | -14.3% | 24,398 | -13.5% | 0.00% | -33.3% |
| Q3 2016 | $2,001,000 | +79.6% | 28,202 | +23.8% | 0.00% | +50.0% |
| Q2 2016 | $1,114,000 | -42.1% | 22,781 | -25.0% | 0.00% | -33.3% |
| Q1 2016 | $1,923,000 | +86.9% | 30,368 | +230.9% | 0.00% | +50.0% |
| Q4 2015 | $1,029,000 | +14.0% | 9,177 | -2.1% | 0.00% | 0.0% |
| Q3 2015 | $903,000 | +8.0% | 9,373 | +14.8% | 0.00% | 0.0% |
| Q2 2015 | $836,000 | +89.1% | 8,163 | +14.6% | 0.00% | +100.0% |
| Q1 2015 | $442,000 | – | 7,123 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |